The Study Thirty-two patients were signed up for this single-arm.

The authors concluded: Perifosine + lenalidomide + dexamethasone was well tolerated and demonstrated encouraging clinical activity in relapsed and relapsed/refractory multiple myeloma . Juergen Engel, PhD, CEO and President of Aeterna Zentaris stated, Results of the study including the new exploratory pharmacodynamic data are one of the good reasons which encouraged us to continue our Phase 3 study with perifosine in multiple myeloma. .. Aeterna Zentaris announces results from perifosine Phase 1 trial on multiple myeloma Aeterna Zentaris Inc. The article outlines the safety profile and encouraging scientific activity of perifosine when combined with dexamethasone and lenalidomide in relapsed and relapsed/refractory multiple myeloma.Second, the Administration has not only released a thorough document outlining the Global Health Initiative, with particular targets for stopping maternal-child HIV transmissions, but also a comprehensive PEPFAR five-year strategy, the spokesperson stated . This content is republished with kind permission from our friends at The Kaiser Family Foundation. You can view the complete Kaiser Daily Health Policy Statement, search the archives, or sign up for email delivery of in-depth coverage of health policy developments, debates and discussions. The Kaiser Daily Health Policy Report is released for Kaisernetwork.org, a free of charge service of The Henry J. Kaiser Family Foundation. Copyright 2009 Advisory Board Organization and Kaiser Family Base.